Moreover, MAD2-overexpressing patients may benefit from MAD2-targeted therapy, which could dramatically dysregulate the cell cycle, effectively activate apoptosis and weaken the proliferation, metastasis, and stemness of tumor cells [43–47]. Here, MAD2L1 is linked to neoplasm.